JPWO2020204033A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020204033A5 JPWO2020204033A5 JP2021512150A JP2021512150A JPWO2020204033A5 JP WO2020204033 A5 JPWO2020204033 A5 JP WO2020204033A5 JP 2021512150 A JP2021512150 A JP 2021512150A JP 2021512150 A JP2021512150 A JP 2021512150A JP WO2020204033 A5 JPWO2020204033 A5 JP WO2020204033A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- acid sequence
- seq
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019070120 | 2019-04-01 | ||
| JP2019070120 | 2019-04-01 | ||
| PCT/JP2020/014832 WO2020204033A1 (ja) | 2019-04-01 | 2020-03-31 | がん治療用医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020204033A1 JPWO2020204033A1 (https=) | 2020-10-08 |
| JPWO2020204033A5 true JPWO2020204033A5 (https=) | 2023-02-20 |
| JP7549889B2 JP7549889B2 (ja) | 2024-09-12 |
Family
ID=72668636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512150A Active JP7549889B2 (ja) | 2019-04-01 | 2020-03-31 | がん治療用医薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220193064A1 (https=) |
| EP (1) | EP3949990A4 (https=) |
| JP (1) | JP7549889B2 (https=) |
| KR (1) | KR20210144767A (https=) |
| CN (1) | CN113660954B (https=) |
| AU (1) | AU2020255907A1 (https=) |
| CA (1) | CA3135157A1 (https=) |
| IL (1) | IL286680A (https=) |
| TW (1) | TWI862564B (https=) |
| WO (1) | WO2020204033A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230398227A1 (en) * | 2020-10-05 | 2023-12-14 | Chiome Bioscience Inc. | Medicine for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| CN1304046C (zh) * | 2004-06-29 | 2007-03-14 | 上海人类基因组研究中心 | 肝癌相关基因dlk1及其应用 |
| KR101512203B1 (ko) * | 2006-11-10 | 2015-04-15 | 가부시키가이샤 리부텍쿠 | ｉｎ ｖｉｖｏ 에서 항종양 활성을 갖는 항인간 Ｄｌｋ－１ 항체 |
| US8017118B2 (en) * | 2008-03-17 | 2011-09-13 | LivTech Inc. — Teikyo University Biotechnology Research Center | Anti-hDlk-1 antibody having an antitumor activity in vivo |
| JPWO2014017524A1 (ja) | 2012-07-26 | 2016-07-11 | デンカ株式会社 | 樹脂組成物 |
| WO2014054820A1 (ja) * | 2012-10-03 | 2014-04-10 | 株式会社リブテック | in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体 |
| HUE056289T2 (hu) * | 2017-02-08 | 2022-02-28 | Adc Therapeutics Sa | Pirrolobenzodiazepin-antitest konjugátumok |
-
2020
- 2020-03-31 CN CN202080026567.XA patent/CN113660954B/zh active Active
- 2020-03-31 CA CA3135157A patent/CA3135157A1/en active Pending
- 2020-03-31 KR KR1020217033277A patent/KR20210144767A/ko active Pending
- 2020-03-31 TW TW109110983A patent/TWI862564B/zh active
- 2020-03-31 WO PCT/JP2020/014832 patent/WO2020204033A1/ja not_active Ceased
- 2020-03-31 JP JP2021512150A patent/JP7549889B2/ja active Active
- 2020-03-31 US US17/599,820 patent/US20220193064A1/en active Pending
- 2020-03-31 EP EP20784328.5A patent/EP3949990A4/en active Pending
- 2020-03-31 AU AU2020255907A patent/AU2020255907A1/en active Pending
-
2021
- 2021-09-26 IL IL286680A patent/IL286680A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514664A5 (https=) | ||
| JP2009525764A5 (https=) | ||
| TWI457124B (zh) | 包含專一性辨識ｃｄ３８之抗體及長春新鹼（ｖｉｎｃｒｉｓｔｉｎｅ）之抗腫瘤組合 | |
| ES2387809T3 (es) | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano | |
| EP2630160B1 (en) | Erbb3 binding antibody | |
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2017186337A5 (https=) | ||
| JP2017522861A5 (https=) | ||
| RU2018114904A (ru) | Антитело против garp | |
| JP2022547081A5 (https=) | ||
| JP2010509931A5 (https=) | ||
| JP2022546454A5 (https=) | ||
| CN107108727A (zh) | 对人vegf‑a有异常强的结合亲和力并具有与人vegf‑b的交叉反应性的抗人vegf抗体 | |
| JP2023526224A (ja) | がんを治療するための、がん治療薬との組合せでの多量体抗ｄｒ５結合分子の使用 | |
| JP2024016024A5 (https=) | ||
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| WO2022237666A1 (zh) | 一种抗Claudin18.2抗体及其抗体药物偶联物 | |
| JP2026048890A (ja) | 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ | |
| EP2710038B1 (en) | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER | |
| JPWO2020204033A5 (https=) | ||
| EP3297668B1 (en) | Combination of anti-fgfr4-antibody and bile acid sequestrant | |
| RU2021131352A (ru) | Лекарственное средство для лечения рака | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| JPWO2016163433A1 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| JP7848119B2 (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲートとｈｅｒ二量体化阻害剤の組み合わせ |